Enzolytics Inc ENZC:OTCPK

*Data is delayed | Exchange | USD
Last | 3:59 PM EDT
0.0043quote price arrow up+0.0008 (+22.8571%)
Volume
21,629,372
52 week range
0.00 - 0.13
Loading...
  • Open0.0031
  • Day High0.0044
  • Day Low0.0031
  • Prev Close0.0035
  • 52 Week High0.13
  • 52 Week High Date05/11/23
  • 52 Week Low0.00
  • 52 Week Low Date04/22/24

Key Stats

  • Market Cap12.774M
  • Shares Out2.97B
  • 10 Day Average Volume23.12M
  • Dividend-
  • Dividend Yield-
  • Beta1.15
  • YTD % Change-75.43

KEY STATS

  • Open0.0031
  • Day High0.0044
  • Day Low0.0031
  • Prev Close0.0035
  • 52 Week High0.13
  • 52 Week High Date05/11/23
  • 52 Week Low0.00
  • 52 Week Low Date04/22/24
  • Market Cap12.774M
  • Shares Out2.97B
  • 10 Day Average Volume23.12M
  • Dividend-
  • Dividend Yield-
  • Beta1.15
  • YTD % Change-75.43

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-87,789.997
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-19.07%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Enzolytics Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Enzolytics, Inc. is a drug development company. The Company is engaged in the commercialization of its proteins and monoclonal antibodies for the treatment of debilitating infectious diseases. Its patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF) for the treatment of human immunodeficiency virus/ acquired immunodeficiency syndrome (HIV/AIDS). It has a technology for producing fully human...
Address
120 W Pomona Ave
Monrovia, CA
91016
United States